Abstract

) The Fox Chase Cancer Center's mission is to reduce the burden of human cancer through the pursuit of new knowledge in basic biological research; the conduct of research specifically related to cancer etiology, treatment and prevention; and the application of new knowledge to the prevention of cancer and the compassionate care and treatment of all cancer patients. Fox Chase is one of only a few free-standing comprehensive centers in the country, and functions as a single, integrated institution, governed by a common board and management structure, and united by its single mission of reducing the burden of human cancer. This Cancer Center Support Grant requests continued support for professional personnel including senior and program leadership, administration and staff investigators; and planning and evaluation. Supporting the thirteen established, peer-reviewed research programs are 27 shared facilities, and developmental funds for new investigators, pilot projects and emerging facilities.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-40
Application #
6512270
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1979-07-01
Project End
2005-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
40
Fiscal Year
2002
Total Cost
$7,514,810
Indirect Cost

  Institution

Name
Fox Chase Cancer Center
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19111

  Publications

Mazor, Anna M; Mateo, Alina M; Demora, Lyudmila et al. (2018) Breast conservation versus mastectomy in patients with T3 breast cancers (>?5 cm): an analysis of 37,268 patients from the National Cancer Database. Breast Cancer Res Treat :
Ingram, Justin P; Tursi, Sarah; Zhang, Ting et al. (2018) A Nonpyroptotic IFN-?-Triggered Cell Death Mechanism in Nonphagocytic Cells Promotes Salmonella Clearance In Vivo. J Immunol 200:3626-3634
Chang, Wen-Chi L; Jackson, Christina; Riel, Stacy et al. (2018) Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas. Gut 67:1290-1298
Mishra, Om P; Popov, Anatoliy V; Pietrofesa, Ralph A et al. (2018) Synthetic secoisolariciresinol diglucoside (LGM2605) inhibits myeloperoxidase activity in inflammatory cells. Biochim Biophys Acta Gen Subj 1862:1364-1375
Mortazavi, S M J; Bevelacqua, J J; Fornalski, K W et al. (2018) Comments on ""Space: The Final Frontier-Research Relevant to Mars"". Health Phys 114:344-345
Esposito, Andrew C; Crawford, James; Sigurdson, Elin R et al. (2018) Omission of radiotherapy after breast conservation surgery in the postneoadjuvant setting. J Surg Res 221:49-57
Dong, Yanqun; Zaorsky, Nicholas G; Li, Tianyu et al. (2018) Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. J Med Imaging Radiat Oncol 62:116-121
Ge, Yunhui; Borne, Elias; Stewart, Shannon et al. (2018) Simulations of the regulatory ACT domain of human phenylalanine hydroxylase (PAH) unveil its mechanism of phenylalanine binding. J Biol Chem 293:19532-19543
Chow, H Y; Dong, B; Valencia, C A et al. (2018) Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer. Nat Commun 9:3473
Egleston, Brian L; Pedraza, Omar; Wong, Yu-Ning et al. (2018) Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible. Contemp Clin Trials Commun 9:135-142

Showing the most recent 10 out of 1280 publications